Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?. Issue 11 (November 2014)

• Record Type: Journal Article
• Authors: Hu, Brian; Goldkorn, Amir
• Is Part Of: Expert review of anticancer therapy. Volume 14:Issue 11(2014)
• Page Start: 1257
• Page End: 1260
• Publication Date: 2014-11
• Subjects: Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.2014.957190
• Languages: English
• ISSNs: 1473-7140

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Prostate specific antigen has been extensively studied and represents the most common biomarker across the spectrum of prostate cancer. Circulating tumor cells are a more recent method for monitoring patients with metastatic prostate cancer and have shown great promise in predicting outcomes. We review the prognostic capabilities of these markers to determine if circulating tumor cells should unseat prostate specific antigen as the test of choice in prostate cancer.</p> </abstract>